Interleukin (IL)-17A has been shown to represent a key-role cytokine in psoriasis pathogenesis; recently, several studies have summarized the efficacy and safety data of two currently approved biologics inhibiting this inflammatory pathway, namely secukinumab and ixekizumab, both showing high rates of maintained skin clearance and low incidence of adverse events.
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients
Cariti, C;Mastorino, LCo-first
;Ortoncelli, M;Siliquini, N;Avallone, G;Fabrizio, R;Susca, S;Quaglino, PCo-last
;Ribero, S
2022-01-01
Abstract
Interleukin (IL)-17A has been shown to represent a key-role cytokine in psoriasis pathogenesis; recently, several studies have summarized the efficacy and safety data of two currently approved biologics inhibiting this inflammatory pathway, namely secukinumab and ixekizumab, both showing high rates of maintained skin clearance and low incidence of adverse events.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
